Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 19-Nov-21 1:30 PM View:  | Harrison Rosemary See Remarks | Trillium Therapeutics Inc. (TRIL) | 17-Nov-21 | Disposition | 75 | -- | -- | (100%) 75 to 0 | |
| 19-Nov-21 3:34 PM View: | Walker Paul Edward Director | Trillium Therapeutics Inc. (TRIL) | 17-Nov-21 | Disposition | 5,736,360 | -- | -- | (100%) 5.74M to 0 | |
| 09-Jul-21 4:30 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 07-Jul-21 | Market Option Sale (Planned) | 3,646 | $9.00 | $32,814.00 | (100%) 3.65K to 0 | |
| 09-Jul-21 4:30 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 07-Jul-21 | Option Exercise | 3,646 | $0.30 | $1,108.02 | 100% 0 to 3.65K | |
| 09-Jun-21 4:23 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 07-Jun-21 | Market Option Sale (Planned) | 3,646 | $8.27 | $30,152.40 | (100%) 3.65K to 0 | |
| 09-Jun-21 4:23 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 07-Jun-21 | Option Exercise | 3,646 | $0.31 | $1,148.49 | 100% 0 to 3.65K | |
| 13-May-21 4:12 PM View: | Skvarka Jan President and CEO Director | Trillium Therapeutics Inc. (TRIL) | 12-May-21 | Market Option Sale | 23,802 | $9.24 | $219,880.00 | (100%) 23.8K to 0 | 13% |
| 13-May-21 4:12 PM View: | Skvarka Jan President and CEO Director | Trillium Therapeutics Inc. (TRIL) | 12-May-21 | Option Exercise | 23,802 | $0.31 | $7,473.83 | 100% 0 to 23.8K | |
| 13-May-21 4:12 PM View: | Skvarka Jan President and CEO Director | Trillium Therapeutics Inc. (TRIL) | 11-May-21 | Option Exercise | 106,698 | $0.42 | $45,070.70 | 100% 0 to 106.7K | |
| 13-May-21 4:12 PM View: | Skvarka Jan President and CEO Director | Trillium Therapeutics Inc. (TRIL) | 11-May-21 | Market Option Sale | 106,698 | $9.20 | $981,803.00 | (100%) 106.7K to 0 | 13% |
| 11-May-21 4:24 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 07-May-21 | Option Exercise | 3,646 | $0.31 | $1,141.20 | 100% 0 to 3.65K | |
| 11-May-21 4:24 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 07-May-21 | Market Option Sale (Planned) | 3,646 | $9.30 | $33,907.80 | (100%) 3.65K to 0 | 14% |
| 09-Apr-21 5:23 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 08-Apr-21 | Market Option Sale (Planned) | 5,312 | $11.09 | $58,910.10 | (100%) 5.31K to 0 | 28% |
| 09-Apr-21 5:23 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 08-Apr-21 | Option Exercise | 5,312 | $1.80 | $9,577.69 | 100% 0 to 5.31K | |
| 09-Apr-21 5:38 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 07-Apr-21 | Market Option Sale (Planned) | 3,646 | $10.82 | $39,449.70 | (100%) 3.65K to 0 | 26% |
| 09-Apr-21 5:38 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 07-Apr-21 | Option Exercise | 3,646 | $0.30 | $1,098.18 | 100% 0 to 3.65K | |
| 15-Mar-21 5:12 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 12-Mar-21 | Market Option Sale (Planned) | 2,917 | $11.97 | $34,916.50 | (100%) 2.92K to 0 | 33% |
| 15-Mar-21 5:12 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 12-Mar-21 | Option Exercise | 2,917 | $3.39 | $9,895.63 | 100% 0 to 2.92K | |
| 12-Mar-21 4:40 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 10-Mar-21 | Option Exercise | 5,312 | $1.80 | $9,545.30 | 100% 0 to 5.31K | |
| 12-Mar-21 4:40 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 10-Mar-21 | Market Option Sale (Planned) | 5,312 | $11.08 | $58,857.00 | (100%) 5.31K to 0 | 28% |
| 10-Mar-21 5:57 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 08-Mar-21 | Option Exercise | 3,646 | $0.30 | $1,093.44 | 100% 0 to 3.65K | |
| 10-Mar-21 5:57 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 08-Mar-21 | Market Option Sale (Planned) | 3,646 | $10.11 | $36,861.10 | (100%) 3.65K to 0 | 21% |
| 10-Feb-21 7:18 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 09-Feb-21 | Market Option Sale (Planned) | 508 | $14.17 | $7,200.39 | (100%) 0.51K to 0 | 43% |
| 10-Feb-21 7:18 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 09-Feb-21 | Market Option Sale (Planned) | 584 | $14.12 | $8,248.42 | (100%) 0.58K to 0 | 43% |
| 10-Feb-21 7:18 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 09-Feb-21 | Option Exercise | 584 | $9.62 | $5,618.84 | 100% 0 to 0.58K | |
| 10-Feb-21 7:18 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 09-Feb-21 | Option Exercise | 508 | $9.62 | $4,887.62 | 100% 0 to 0.51K | |
| 10-Feb-21 7:18 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 08-Feb-21 | Market Option Sale (Planned) | 5,312 | $12.65 | $67,196.80 | (100%) 5.31K to 0 | 37% |
| 10-Feb-21 7:18 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 08-Feb-21 | Market Option Sale (Planned) | 6,563 | $12.65 | $83,021.90 | (100%) 6.56K to 0 | 37% |
| 10-Feb-21 7:18 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 08-Feb-21 | Option Exercise | 6,563 | $1.64 | $10,751.50 | 100% 0 to 6.56K | |
| 10-Feb-21 7:18 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 08-Feb-21 | Option Exercise | 5,312 | $1.78 | $9,435.05 | 100% 0 to 5.31K | |
| 15-Jan-21 4:19 PM View: | Skvarka Jan President and CEO Director | Trillium Therapeutics Inc. (TRIL) | 14-Jan-21 | Option Exercise | 19,581 | $0.43 | $8,370.88 | 100% 0 to 19.58K | |
| 15-Jan-21 4:19 PM View: | Skvarka Jan President and CEO Director | Trillium Therapeutics Inc. (TRIL) | 14-Jan-21 | Market Option Sale (Planned) | 19,581 | $15.03 | $294,279.00 | (100%) 19.58K to 0 | 47% |
| 15-Jan-21 4:19 PM View: | Skvarka Jan President and CEO Director | Trillium Therapeutics Inc. (TRIL) | 13-Jan-21 | Market Option Sale (Planned) | 5,419 | $15.04 | $81,507.70 | (100%) 5.42K to 0 | 47% |
| 15-Jan-21 4:19 PM View: | Skvarka Jan President and CEO Director | Trillium Therapeutics Inc. (TRIL) | 13-Jan-21 | Option Exercise | 5,419 | $0.42 | $2,301.99 | 100% 0 to 5.42K | |
| 13-Jan-21 4:12 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 11-Jan-21 | Option Exercise | 584 | $9.57 | $5,587.19 | 100% 0 to 0.58K | |
| 13-Jan-21 4:11 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 11-Jan-21 | Option Exercise | 508 | $9.57 | $4,860.09 | 100% 0 to 0.51K | |
| 13-Jan-21 4:11 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 11-Jan-21 | Market Option Sale (Planned) | 508 | $15.21 | $7,725.31 | (100%) 0.51K to 0 | 47% |
| 13-Jan-21 4:12 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 11-Jan-21 | Market Option Sale (Planned) | 584 | $15.20 | $8,878.67 | (100%) 0.58K to 0 | 47% |
| 12-Jan-21 4:12 PM View: | Parsons James T. Chief Financial Officer | Trillium Therapeutics Inc. (TRIL) | 08-Jan-21 | Option Exercise | 8,505 | $7.24 | $61,616.20 | 100% 0 to 8.51K | |
| 12-Jan-21 4:10 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 08-Jan-21 | Market Option Sale (Planned) | 2,604 | $15.50 | $40,364.60 | (100%) 2.6K to 0 | 48% |
| 12-Jan-21 4:11 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 08-Jan-21 | Market Option Sale (Planned) | 8,517 | $15.71 | $133,806.00 | (100%) 8.52K to 0 | 49% |
| 12-Jan-21 4:12 PM View: | Parsons James T. Chief Financial Officer | Trillium Therapeutics Inc. (TRIL) | 08-Jan-21 | Market Option Sale (Planned) | 8,505 | $15.79 | $134,271.00 | (100%) 8.51K to 0 | 49% |
| 12-Jan-21 4:11 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 08-Jan-21 | Option Exercise | 8,517 | $8.38 | $71,365.20 | 100% 0 to 8.52K | |
| 12-Jan-21 4:10 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 08-Jan-21 | Option Exercise | 2,604 | $3.33 | $8,673.92 | 100% 0 to 2.6K | |
| 11-Jan-21 4:17 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 07-Jan-21 | Market Option Sale (Planned) | 3,646 | $14.75 | $53,782.10 | (100%) 3.65K to 0 | 46% |
| 11-Jan-21 4:17 PM View: | Uger Robert Chief Scientific Officer | Trillium Therapeutics Inc. (TRIL) | 07-Jan-21 | Option Exercise | 3,646 | $0.30 | $1,089.06 | 100% 0 to 3.65K | |
| 11-Jan-21 4:19 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 07-Jan-21 | Option Exercise | 2,708 | $0.30 | $808.88 | 100% 0 to 2.71K | |
| 11-Jan-21 4:19 PM View: | Petrova Penka Chief Development Officer | Trillium Therapeutics Inc. (TRIL) | 07-Jan-21 | Market Option Sale (Planned) | 2,708 | $14.71 | $39,842.80 | (100%) 2.71K to 0 | 45% |
